New findings from Lund University, published in the March issue of Nature Communications, shows that the cause of the accumulation of beta-amyloid in the brain is more diverse than previously thought. There may be significant for the development of drugs against Alzheimer’s, says Swedish Brain Power researchers Niklas Mattsson and Oskar Hansson.
– Our study shows that people with deposition of beta-amyloid in the brain, often have elevated levels of certain variants of the beta amyloid also in the spinal fluid. This may mean that they have increased production of beta-amyloid, even if they do not carry the genetic risk gene for Alzheimer’s, explains Niklas Mattsson, researcher at Lund University and specialist at Skåne University Hospital.
That the disease can be traced to both overproduction and problems to break down beta-amyloid may have implications for future designing of drugs and treatments.
– Our results are important because they increase the understanding of how Alzheimer’s occurs. Our hope is that this and other similar studies can increase the ability to personalize future disease treatments, says Oskar Hansson, associate professor at Lund University and physician at Skåne University Hospital.
Other Swedish Brain Power researchers who contributed to the study are Erik Stormrud, Lennart Minthon, Henrik Zetterberg and Kaj Blennow.